Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Replimune Group (NASDAQ: REPL) announced inducement equity awards for 34 newly hired non-executive employees. The awards include non-qualified stock options to purchase 58,240 shares at $14.25 per share (closing price on February 5, 2025) and restricted stock units (RSUs) for 116,680 shares.
The stock options have a 10-year term with a four-year vesting schedule: 25% vests after one year, with the remainder vesting monthly over three years. The RSUs vest in approximately equal annual installments starting February 15, 2026. These inducement awards, approved under Nasdaq Rule 5635(c)(4), align with the terms of the company's 2018 Equity Incentive Plan despite being granted outside it.
Replimune Group (NASDAQ: REPL) ha annunciato premi azionari di indennizzo per 34 nuovi dipendenti non esecutivi. I premi includono opzioni su azioni non qualificate per l'acquisto di 58.240 azioni a $14.25 per azione (prezzo di chiusura del 5 febbraio 2025) e unità di azioni vincolate (RSU) per 116.680 azioni.
Le opzioni su azioni hanno una durata di 10 anni con un programma di maturazione di quattro anni: il 25% diventa disponibile dopo un anno, con il resto che matura ogni mese per tre anni. Le RSU maturano in rate annuali approssimativamente uguali a partire dal 15 febbraio 2026. Questi premi di indennizzo, approvati ai sensi della Regola Nasdaq 5635(c)(4), sono in linea con i termini del Piano di Incentivazione Azionaria del 2018 dell'azienda, nonostante siano concessi al di fuori di esso.
Replimune Group (NASDAQ: REPL) anunció premios de acciones por inducción para 34 nuevos empleados no ejecutivos. Los premios incluyen opciones sobre acciones no calificadas para comprar 58,240 acciones a $14.25 por acción (precio de cierre del 5 de febrero de 2025) y unidades de acciones restringidas (RSUs) para 116,680 acciones.
Las opciones sobre acciones tienen un plazo de 10 años con un calendario de adquisición de cuatro años: el 25% se adquiere después de un año, con el resto adquiriéndose mensualmente durante tres años. Las RSUs se adquieren en cuotas anuales aproximadamente iguales a partir del 15 de febrero de 2026. Estos premios de inducción, aprobados bajo la Regla 5635(c)(4) de Nasdaq, se alinean con los términos del Plan de Incentivo de Equidad de 2018 de la compañía a pesar de ser otorgados fuera de él.
Replimune Group (NASDAQ: REPL)이 34명의 새로 고용된 비상임 직원에게 유도 성격의 주식 보상을 발표했습니다. 보상에는 비 자격 주식 옵션이 포함되어 있으며, 이는 58,240주를 주당 $14.25에 구매할 수 있으며 (2025년 2월 5일의 종가) 제한된 주식 단위 (RSU)가 116,680주입니다.
주식 옵션은 10년의 기간을 가지며 4년의 취득 일정이 있습니다: 1년 후 25%가 취득 가능하며, 나머지는 3년 동안 매월 취득됩니다. RSU는 2026년 2월 15일부터 시작하여 대략 동일한 연간 할부로 취득됩니다. 이러한 유도 보상은 나스닥 규칙 5635(c)(4)에 따라 승인되었으며, 회사의 2018년 주식 인센티브 계획의 조건과 일치하나 그 밖에서 부여됩니다.
Replimune Group (NASDAQ: REPL) a annoncé l'attribution de récompenses d'actions pour incitation à 34 nouveaux employés non exécutifs. Les récompenses comprennent des options d'achat d'actions non qualifiées pour l'acquisition de 58 240 actions à 14,25 $ par action (prix de clôture au 5 février 2025) et des unités d'actions restreintes (RSU) pour 116 680 actions.
Les options d'achat d'actions ont une durée de 10 ans avec un calendrier d'acquisition sur quatre ans : 25 % sont acquises après un an, le reste étant acquis mensuellement sur trois ans. Les RSUs s'acquièrent par versements annuels approximativement égaux à partir du 15 février 2026. Ces récompenses d'incitation, approuvées selon la règle 5635(c)(4) de Nasdaq, sont conformes aux conditions du Plan d'Incitation à l'Équité de l'entreprise de 2018, bien qu'elles aient été octroyées en dehors de celui-ci.
Replimune Group (NASDAQ: REPL) gab Anreize für Aktienvergaben an 34 neu eingestellte nicht-executive Mitarbeiter bekannt. Die Vergaben umfassen nicht qualifizierte Aktienoptionen zum Kauf von 58.240 Aktien zu einem Preis von 14,25 $ pro Aktie (Schlusskurs am 5. Februar 2025) und eingeschränkte Aktieneinheiten (RSUs) für 116.680 Aktien.
Die Aktienoptionen haben eine Laufzeit von 10 Jahren mit einem vierjährigen Vesting-Plan: 25% werden nach einem Jahr fällig, der Rest vestet monatlich über drei Jahre. Die RSUs vesten in ungefähr gleichmäßigen jährlichen Raten, beginnend am 15. Februar 2026. Diese Anreizvergaben, die gemäß Nasdaq-Regel 5635(c)(4) genehmigt wurden, stehen im Einklang mit den Bedingungen des Unternehmens 2018 Equity Incentive Plans, obwohl sie außerhalb davon vergeben wurden.
- None.
- None.
WOBURN, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees.
The Company granted equity awards to 34 employees as a material inducement to commencing their employment with the Company. The inducement awards consist of non-qualified stock options to purchase an aggregate of 58,240 shares of the Company's common stock and restricted stock units representing an aggregate of 116,680 shares of the Company's common stock. Each option has an exercise price of
The aforementioned inducement awards were approved by the compensation committee of the Company's board of directors in reliance on the employment inducement exception under Nasdaq Listing Rule 5635(c)(4). While the inducement awards were granted outside of the Company’s 2018 Equity Incentive Plan, the awards will have terms and conditions consistent with those set forth under such plan.
About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to ignite a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.
Investor Inquiries
Chris Brinzey
ICR Westwicke
339.970.2843
chris.brinzey@westwicke.com
Media Inquiries
Arleen Goldenberg
Replimune
917.548.1582
media@replimune.com
FAQ
How many shares are included in Replimune's (REPL) February 2025 inducement grants?
What is the exercise price for REPL's February 2025 inducement stock options?
What is the vesting schedule for REPL's February 2025 inducement stock options?
When do the restricted stock units (RSUs) from REPL's February 2025 inducement grants begin vesting?
